| Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient. | |
| | |
MedLine Citation:
|
PMID: 20138360 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome 13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM. |
| | |
Authors:
|
Ji Yuan; Radhika Shah; Anita Kulharya; Celalettin Ustun |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Leukemia research Volume: 34 ISSN: 1873-5835 ISO Abbreviation: Leuk. Res. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-06-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7706787 Medline TA: Leuk Res Country: England |
Other Details:
|
Languages: eng Pagination: 954-7 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Pathology, Medical College of Georgia, Augusta, GA 30912, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
pharmacology*,
therapeutic use Antineoplastic Agents / pharmacology* Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Boronic Acids / administration & dosage, pharmacology* Chromosome Deletion* Chromosomes, Human, Pair 13 Chromosomes, Human, Pair 14 / ultrastructure Chromosomes, Human, Pair 8 / ultrastructure Clone Cells / drug effects, ultrastructure Combined Modality Therapy Dexamethasone / administration & dosage Drug Resistance, Neoplasm / genetics* Female Humans Karyotyping Middle Aged Multiple Myeloma / drug therapy, genetics*, pathology, surgery Neoplastic Stem Cells / drug effects*, ultrastructure Peripheral Blood Stem Cell Transplantation Polyploidy* Protease Inhibitors / pharmacology*, therapeutic use Pyrazines / administration & dosage, pharmacology* Thalidomide / administration & dosage, analogs & derivatives*, pharmacology Translocation, Genetic Transplantation, Autologous |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib; 191732-72-6/lenalidomide; 50-02-2/Dexamethasone; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients...
Next Document: Cadmium impairs mineral and carbohydrate mobilization during the germination of bean seeds.